These findings strongly suggest that epigenetic silencing of claudin-3 is a common occurrence in CRPC, potentially serving as a valuable molecular marker for predicting the prognosis of prostate cancer patients and differentiating aggressive from indolent prostate tumors. The gene discussed is CLDN3; the disease is prostate cancer.